vascular endothelial growth factor receptor 2 Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group
Sitenames

Any (1)

Unknown (1)

Observational (1)

The First Affiliated Hospital of Zhengzhou University (1)

No (1)

No (1)

Adult (18+) (1)

affili (1)
depart (1)
first (1)
hospit (1)
neurosurgeri (1)
univers (1)
zhengzhou (1)

I am/have/had

I am/have/hadneutrophil count

I am/have/hadglioma

I am/have/hadliver metastasis

I am/have/hadmetastasis

I am/have/hadhypertension

I am/have/hadvascular endothelial growth factor

I am/have/hadvegf

I am/have/hadvascular endothelial growth factor receptor 2

I am/have/hadplatelet count

I am/have/hadtyrosine

I am/have/hadpostoperative complication

added new label for I am/have/had

more

I am looking for

I am looking forvegf

I am looking forvascular endothelial growth factor

I am looking forapatinib

I am looking forgrowth factor

I am looking fortyrosine

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

For Seniors
For adults
Recruiting in 100s
Observational Study
all
Recruiting

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices …

neutrophil count

glioma

liver metastasis

metastasis

apatinib

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.